Using cell cultures and animal models, researchers from the USC Norris Comprehensive Cancer Center at Keck School of Medicine of USC showed that next-generation CAR T cells can safely and effectively shrink solid tumors.
Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.
